Qu Nanfang, Bo Xiaotong, Li Bin, Ma Lei, Wang Feng, Zheng Qinghua, Xiao Xuhua, Huang Fengmei, Shi Yuanyuan, Zhang Xuemei
Department of Gastroenterology, Affiliated Hospital of Guilin Medical University, Guilin, China.
Department of Gastroenterology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Front Oncol. 2021 Oct 7;11:755206. doi: 10.3389/fonc.2021.755206. eCollection 2021.
Liver cancer is the fifth most common malignant tumor in terms of incidence and the third leading cause of cancer-related mortality globally. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Although great progress has been made in surgical techniques, hepatic artery chemoembolization, molecular targeting and immunotherapy, the prognosis of liver cancer patients remains very poor. N-methyladenosine (mA) is the most abundant internal RNA modification in eukaryotic cells and regulates various stages of the RNA life cycle. Many studies have reported that the abnormal expression of m6A-related regulators in HCC represent diagnostic and prognostic markers and potential therapeutic targets. In this review, firstly, we introduce the latest research on mA-related regulators in detail. Next, we summarize the mechanism of each regulator in the pathogenesis and progression of HCC. Finally, we summarize the potential diagnostic, prognostic and therapeutic value of the regulators currently reported in HCC.
就发病率而言，肝癌是全球第五大常见恶性肿瘤，也是癌症相关死亡的第三大主要原因。肝细胞癌（HCC）是原发性肝癌最常见的类型。尽管在手术技术、肝动脉化疗栓塞、分子靶向治疗和免疫治疗方面取得了巨大进展，但肝癌患者的预后仍然很差。N6-甲基腺苷（m6A）是真核细胞中最丰富的内部RNA修饰，可调节RNA生命周期的各个阶段。许多研究报告称，HCC中m6A相关调节因子的异常表达代表了诊断和预后标志物以及潜在的治疗靶点。在本综述中，首先，我们详细介绍了m6A相关调节因子的最新研究。接下来，我们总结了每个调节因子在HCC发病机制和进展中的作用机制。最后，我们总结了目前报道的这些调节因子在HCC中的潜在诊断、预后和治疗价值。
Zotero 插件